Chargement en cours...
Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability
Dacomitinib (DMB) is a second-generation irreversible tyrosine kinase inhibitor (TKI) that is claimed to overcome the disadvantages of the resistance reported for first-line epidermal growth factor receptor (EGFR) TKIs. Towards the end of 2018, the US Food and Drug Administration approved DMB in the...
Enregistré dans:
| Publié dans: | PLoS One |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6448865/ https://ncbi.nlm.nih.gov/pubmed/30947315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0214598 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|